Bausch Health Companies (BHC) Stock Analysis & Winston Score

Bausch Health Companies is a pharmaceutical company that makes and sells prescription drugs, over-the-counter medicines, and medical devices. Its products cover eye health, skin conditions, and gastrointestinal issues, sold mainly to hospitals, pharmacies, and doctors across North America and internationally. The company owns well-known brands like Xifaxan, a prescription drug for irritable bowel syndrome, and has a majority stake in Bausch + Lomb, one of the largest eye health companies in the world. Bausch Health earns money by selling branded and generic drugs, as well as eye care products ranging from contact lenses to surgical equipment. It operates primarily in the United States, Canada, and Europe, generating roughly $8–9 billion in annual revenue. The company carries a very heavy debt load — over $20 billion — left over from an aggressive acquisition strategy years ago, and managing that debt while potentially spinning off its Bausch + Lomb stake remains the central challenge facing the business.